Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RCUS Arcus Biosciences Inc.

盘后交易 03-31 19:07:39 EDT

21.60

+0.95

+4.60%

盘后21.26

-0.34-1.57%

17:17 EDT

最高22.09	最低21.24	成交量146.05万
今开21.24	昨收20.65	日振幅4.12%
总市值27.08亿	流通市值19.15亿	总股本1.25亿
成交额3,161万	换手率1.65%	流通股本8,865万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RCUS","market":"US","secType":"STK","nameCN":"Arcus Biosciences Inc.","latestPrice":21.6,"timestamp":1774987200000,"preClose":20.65,"halted":0,"volume":1460498,"hourTrading":{"tag":"盘后","latestPrice":21.26,"preClose":21.6,"latestTime":"17:17 EDT","volume":121709,"amount":2628912.817783,"timestamp":1774991866182,"change":-0.34,"changeRate":-0.015741,"amplitude":0.015741},"delay":0,"changeRate":0.04600484261501225,"floatShares":88651800,"shares":125349476,"eps":-3.29,"marketStatus":"盘后交易","change":0.95,"latestTime":"03-31 19:07:39 EDT","open":21.24,"high":22.0899,"low":21.24,"amount":31609229.60195,"amplitude":0.041157,"askPrice":21.6,"askSize":2,"bidPrice":21.18,"bidSize":94,"shortable":3,"etf":0,"ttmEps":-3.29,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1775001600000},"marketStatusCode":4,"adr":0,"adrRate":0,"listingDate":1521086400000,"exchange":"NYSE","adjPreClose":20.65,"preHourTrading":{"tag":"盘前","latestPrice":20.99,"preClose":20.65,"latestTime":"09:17 EDT","volume":3676,"amount":77116.330052,"timestamp":1774963047241,"change":0.34,"changeRate":0.016465,"amplitude":0.048426},"postHourTrading":{"tag":"盘后","latestPrice":21.26,"preClose":21.6,"latestTime":"17:17 EDT","volume":121709,"amount":2628912.817783,"timestamp":1774991866182,"change":-0.34,"changeRate":-0.015741,"amplitude":0.015741},"volumeRatio":1.551959,"impliedVol":0.5918,"impliedVolPercentile":0.1155},"requestUrl":"/m/hq/s/RCUS/tweets","defaultTab":"tweets","newsList":[{"id":"1162783278","title":"财报前瞻 ｜Arcus Biosciences Inc.营收预计增25.49%，机构观点偏乐观","url":"https://stock-news.laohu8.com/highlight/detail?id=1162783278","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162783278?lang=zh_cn&edition=full","pubTime":"2026-02-18 12:59","pubTimestamp":1771390762,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.将于2026年02月25日公布新一季财报，市场关注营收与调整后每股收益同比改善的幅度。市场一致预期本季度营收为3626.67万美元，同比增25.49%；调整后每股收益为-1.02美元，同比改善18.09%；息税前利润为-1.21亿美元，同比改善1.23%，毛利率与净利率暂无一致预测数据可供披露。成本端投入延续使得息税前利润为-1.42亿美元，同比降35.24%，但营收较市场预期高出460.00万美元。从近期机构动态看，市场整体观点偏乐观。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜Arcus Biosciences Inc.营收预计增25.49%，机构观点偏乐观","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611110088","title":"Arcus Biosciences, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611110088","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611110088?lang=zh_cn&edition=full","pubTime":"2026-02-14 03:29","pubTimestamp":1771010982,"startTime":"0","endTime":"0","summary":"北京时间2026年02月14日03时29分，Arcus Biosciences, Inc.股票出现异动，股价大幅下挫5.01%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为1.80%。其相关个股中，Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Phio Pharmaceuticals Corp.涨幅较大，Moolec Science Sa、Biorestorative Therapies, Inc.、Quince Therapeutics, Inc.较为活跃，换手率分别为6521.10%、341.03%、273.34%，振幅较大的相关个股有Moolec Science Sa C/Wts 30/01/2028、Moolec Science Sa、Phio Pharmaceuticals Corp.，振幅分别为121.84%、80.59%、54.33%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021403294297a6242a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021403294297a6242a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2611134534","title":"Arcus Biosciences, Inc.盘中异动 临近午盘股价大跌5.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2611134534","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611134534?lang=zh_cn&edition=full","pubTime":"2026-02-13 00:50","pubTimestamp":1770915012,"startTime":"0","endTime":"0","summary":"北京时间2026年02月13日00时50分，Arcus Biosciences, Inc.股票出现波动，股价大幅下跌5.31%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.22%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Galecto, Inc.、Karyopharm Therapeutics Inc.涨幅较大，Onconetix, Inc.、Quince Therapeutics, Inc.、Biorestorative Therapies, Inc.较为活跃，换手率分别为348.20%、186.26%、88.08%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Polaryx Therapeutics, Inc.、Karyopharm Therapeutics Inc.，振幅分别为62.50%、60.77%、35.01%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021300501297a5fd5c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026021300501297a5fd5c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142235368","title":"Arcus Biosciences Inc - 首次修正案将到期日延长至2030年9月1日，且不再有进一步延长权利 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1142235368","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142235368?lang=zh_cn&edition=full","pubTime":"2025-12-19 05:23","pubTimestamp":1766093017,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc - 首次修正案将到期日延长至2030年9月1日，且不再有进一步延长权利 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150596817","title":"Arcus Biosciences Inc.股价在盘前交易中下跌12%，因公司与Gilead终止癌症药物组合的高级阶段试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1150596817","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150596817?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:55","pubTimestamp":1765547723,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.股价在盘前交易中下跌12%，因公司与Gilead终止癌症药物组合的高级阶段试验。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139444356","title":"Arcus公布第3阶段Star-221研究进展，并将研发投资集中于Casdatifan及新兴的炎症与免疫学项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1139444356","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1139444356?lang=zh_cn&edition=full","pubTime":"2025-12-12 21:30","pubTimestamp":1765546225,"startTime":"0","endTime":"0","summary":"Arcus公布第3阶段Star-221研究进展，并将研发投资集中于Casdatifan及新兴的炎症与免疫学项目","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581032877","title":"Arcus Biosciences, Inc.盘中异动 早盘快速跳水5.09%报18.82美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2581032877","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581032877?lang=zh_cn&edition=full","pubTime":"2025-11-05 23:13","pubTimestamp":1762355639,"startTime":"0","endTime":"0","summary":"北京时间2025年11月05日23时13分，Arcus Biosciences, Inc.股票出现波动，股价急速下挫5.09%。截至发稿，该股报18.82美元/股，成交量11.893万股，换手率0.10%，振幅4.29%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.39%。其相关个股中，Pasithea Therapeutics Corp C/Wts 12/08/2026 、Rigel Pharmaceuticals, Inc.、Fortrea Holdings Inc.涨幅较大，Lunai Bioworks Inc.、Immuron Limited、Metavia Inc.较为活跃，换手率分别为321.67%、84.33%、61.66%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Ethzilla Corporation C/Wts 06/11/2025、Lunai Bioworks Inc.，振幅分别为84.09%、75.37%、68.59%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105231359a6e38b5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251105231359a6e38b5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135952223","title":"异动解读 | Arcus Biosciences股票盘前大跌6.39%，2.5亿美元折价配股成主因","url":"https://stock-news.laohu8.com/highlight/detail?id=1135952223","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135952223?lang=zh_cn&edition=full","pubTime":"2025-10-31 20:03","pubTimestamp":1761912206,"startTime":"0","endTime":"0","summary":"生物制药公司Arcus Biosciences Inc.今日盘前股价大跌6.39%，引发市场关注。据悉，此次股价下跌主要源于公司在周四晚间宣布的一项2.5亿美元的后续股票发行。Arcus Biosciences以每股18.25美元的价格发行了1370万股新股，较之前的股价有9.6%的折扣。这一消息导致投资者对公司股票的估值产生了担忧，从而引发了股价下跌。值得注意的是，尽管此次股价下跌，Arcus Biosciences的股票今年以来仍有不俗表现，截至周四收盘累计上涨约36%。然而，这次大规模融资可能会在短期内对股价造成压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108675051","title":"异动解读 | Arcus Biosciences盘后大跌5.84%，宣布新股发行计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1108675051","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108675051?lang=zh_cn&edition=full","pubTime":"2025-10-31 05:01","pubTimestamp":1761858065,"startTime":"0","endTime":"0","summary":"生物制药公司Arcus Biosciences在周四盘后交易中股价大跌5.84%，收于19.05美元。此次下跌主要源于公司宣布了新股发行计划，引发了投资者对潜在股权稀释的担忧。据悉，Arcus Biosciences正寻求通过股票发行进行融资，但具体发行规模尚未披露。该公司已委托Leerink Partners和高盛担任此次发行的联合账簿管理人。作为一家专注于开发癌症、炎症和自身免疫疾病疗法的生物制药公司，Arcus Biosciences目前拥有约1.08亿股流通股，市值约20亿美元。尽管股价出现回调，但Arcus Biosciences的市场前景仍然看好。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2579949188","title":"Arcus Biosciences, Inc.盘中异动 股价大涨5.03%报20.88美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2579949188","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579949188?lang=zh_cn&edition=full","pubTime":"2025-10-29 21:59","pubTimestamp":1761746393,"startTime":"0","endTime":"0","summary":"北京时间2025年10月29日21时59分，Arcus Biosciences, Inc.股票出现波动，股价大幅上涨5.03%。截至发稿，该股报20.88美元/股，成交量43.7778万股，换手率0.41%，振幅5.11%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.68%。其相关个股中，Purple Biotech Ltd、Surrozen Inc C/Wts 01/08/2031 、Ernexa Therapeutics Inc.涨幅较大，Purple Biotech Ltd、Ernexa Therapeutics Inc.、Aditxt, Inc.较为活跃，换手率分别为2649.02%、1096.06%、240.57%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Purple Biotech Ltd、Ernexa Therapeutics Inc.，振幅分别为132.00%、70.34%、40.79%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510292159539748a7fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202510292159539748a7fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105686983","title":"抗TIGIT药物Domvanalimab联合抗PD-1药物Zimberelimab及化疗作为不可切除或晚期胃食管腺癌一线治疗在2期Edge-Gastric研究中显示26.7个月中位总生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=1105686983","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105686983?lang=zh_cn&edition=full","pubTime":"2025-10-13 06:07","pubTimestamp":1760306836,"startTime":"0","endTime":"0","summary":"抗TIGIT药物Domvanalimab联合抗PD-1药物Zimberelimab及化疗作为不可切除或晚期胃食管腺癌一线治疗在2期Edge-Gastric研究中显示26.7个月中位总生存期","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102176506","title":"Arcus Biosciences Inc.：四个单药治疗队列汇总分析显示中位无进展生存期达12.2个月，18个月里程碑式无进展生存率为43%","url":"https://stock-news.laohu8.com/highlight/detail?id=1102176506","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102176506?lang=zh_cn&edition=full","pubTime":"2025-10-06 20:15","pubTimestamp":1759752924,"startTime":"0","endTime":"0","summary":"Arcus Biosciences Inc.公布最新临床数据，在对四个单药治疗队列进行的汇总分析中，患者的中位无进展生存期为12.2个月，18个月里程碑式无进展生存率达到43%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518271566","title":"Arcus Biosciences, Inc.盘中异动 早盘大幅跳水5.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518271566","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518271566?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:23","pubTimestamp":1741616619,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时23分，Arcus Biosciences, Inc.股票出现波动，股价快速下跌5.22%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.49%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3406.15%、721.29%、415.10%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022233998a2a9f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022233998a2a9f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516665940","title":"Arcus Biosciences, Inc.盘中异动 临近收盘大幅下跌5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516665940","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516665940?lang=zh_cn&edition=full","pubTime":"2025-03-04 04:37","pubTimestamp":1741034235,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日04时37分，Arcus Biosciences, Inc.股票出现波动，股价急速跳水5.05%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体跌幅为0.18%。其相关个股中，Abpro Holdings Inc C/Wts 12/11/2029 、Cardio Diagnostics Holdings Inc C/Wts  To Pur Com、Celularity Inc C/Wts 16/07/2026 涨幅较大，Allarity Therapeutics, Inc.、Entero Therapeutics Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为215.44%、187.68%、163.59%，振幅较大的相关个股有Radiopharm Theranostics Limited、Entero Therapeutics Inc.、Celularity Inc C/Wts 16/07/2026 ，振幅分别为119.50%、70.53%、64.88%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043715989a60bf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304043715989a60bf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2516557562","title":"Arcus Biosciences, Inc.2024财年实现净利润-2.83亿美元，同比增加7.82%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516557562","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516557562?lang=zh_cn&edition=full","pubTime":"2025-03-02 00:01","pubTimestamp":1740844883,"startTime":"0","endTime":"0","summary":"3月2日，Arcus Biosciences, Inc.公布财报，公告显示公司2024财年净利润为-2.83亿美元，同比增加7.82%；其中营业收入为2.58亿美元，同比增加120.51%，每股基本收益为-3.14美元。机构评级：截至2025年3月2日，当前有11家机构对Arcus Biosciences, Inc.目标价做出预测，其中目标均价为32.55美元，其中最低目标价为17.00美元，最高目标价为46.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000218a259dd46&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250302000218a259dd46&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514378385","title":"Arcus Biosciences, Inc.盘中异动 早盘股价大涨5.77%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514378385","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514378385?lang=zh_cn&edition=full","pubTime":"2025-02-28 22:30","pubTimestamp":1740753029,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时30分，Arcus Biosciences, Inc.股票出现异动，股价大幅上涨5.77%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。其相关个股中，Virpax Pharmaceuticals, Inc.、Bioxcel Therapeutics, Inc.、Ensysce Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Virpax Pharmaceuticals, Inc.、Enveric Biosciences, Inc.较为活跃，换手率分别为480.20%、239.09%、53.23%，振幅较大的相关个股有Tiziana Life Sciences Ltd、Aardvark Therapeutics, Inc.、Lexeo Therapeutics, Inc.，振幅分别为8.85%、6.22%、4.85%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223030abe0e9b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228223030abe0e9b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156992500","title":"异动解读 | 分析师利好评级和财报数据超预期,Arcus Biosciences盘中大涨13.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=1156992500","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156992500?lang=zh_cn&edition=full","pubTime":"2025-02-26 23:13","pubTimestamp":1740582780,"startTime":"0","endTime":"0","summary":"今日盘中,Arcus Biosciences大涨13.38%,引发市场高度关注。有消息指出,这次RCUS盘中大涨的主因可能来自以下两方面:首先,券商H.C. Wainwright将该股评级从\"中性\"上调至\"买入\",并将目标价从18美元大幅上调至24美元。该行分析师认为,RCUS的实验性药物casdatifan有望成为治疗一种名为\"透明细胞肾细胞癌\"的肾癌类型的二线疗法,看好其未来前景。其次,RCUS刚刚公布的2025年第四季度财报数据也令投资者振奋。良好的财报数据反映出公司运营情况向好,增强了市场对该股的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 分析师利好评级和财报数据超预期,Arcus Biosciences盘中大涨13.38%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514856450","title":"Arcus Biosciences, Inc.盘中异动 股价大涨11.23%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514856450","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514856450?lang=zh_cn&edition=full","pubTime":"2025-02-26 22:33","pubTimestamp":1740580398,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时33分，Arcus Biosciences, Inc.股票出现波动，股价大幅上涨11.23%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，Channel Therapeutics Corporation、Nutriband Inc C/Wts 、Immunoprecise Antibodies Ltd.涨幅较大，Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.、Psyence Biomedical Ltd.较为活跃，换手率分别为122.60%、92.20%、74.72%，振幅较大的相关个股有Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.、Organovo Holdings, Inc.，振幅分别为16.86%、14.35%、13.39%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。Arcus针对不同类型的癌症进行临床试验，如肺癌、结肠直肠癌、胰腺癌等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223318a254f703&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223318a254f703&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106972136","title":"Arcus Biosciences第四季度每股亏损$(1.03)优于预期$(1.32)，销售额3600万美元优于预期2890万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106972136","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106972136?lang=zh_cn&edition=full","pubTime":"2025-02-26 05:38","pubTimestamp":1740519531,"startTime":"0","endTime":"0","summary":"Arcus Biosciences 报告季度每股亏损$，优于分析师普遍预期的$，涨幅为21.97%。与去年同期每股亏损$相比，亏损减少4.63%。与去年同期销售额3100万美元相比，增长了16.13%。以上内容来自Benzinga Earnings专栏，原文如下：Arcus Biosciences  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 21.97 percent. This is a 4.63 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $36.00 million which beat the analyst consensus estimate of $28.90 million by 24.57 percent.  This is a 16.13 p","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Arcus Biosciences第四季度每股亏损$(1.03)优于预期$(1.32)，销售额3600万美元优于预期2890万美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513773346","title":"Arcus Biosciences, Inc.盘中异动 早盘快速下跌5.01%报10.52美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513773346","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513773346?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:27","pubTimestamp":1740410825,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时27分，Arcus Biosciences, Inc.股票出现异动，股价大幅下跌5.01%。Arcus Biosciences, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。其相关个股中，Pepgen Inc.、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为200.89%、84.63%、27.77%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、60 Degrees Pharmaceuticals Inc C/Wts 12/07/2028 ，振幅分别为137.23%、55.69%、53.34%。Arcus Biosciences, Inc.公司简介：Arcus Biosciences Inc 是一家临床阶段的生物制药公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232706962ea5e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224232706962ea5e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RCUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arcusbio.com","stockEarnings":[{"period":"1week","weight":-0.0355},{"period":"1month","weight":0.0137},{"period":"3month","weight":-0.1111},{"period":"6month","weight":0.5319},{"period":"1year","weight":1.5275},{"period":"ytd","weight":-0.1334}],"compareEarnings":[{"period":"1week","weight":-0.0357},{"period":"1month","weight":-0.0787},{"period":"3month","weight":-0.0801},{"period":"6month","weight":-0.0546},{"period":"1year","weight":0.1373},{"period":"ytd","weight":-0.0732}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arcus Biosciences, Inc.于2015年4月30日在特拉华州成立。它们是一家临床阶段的生物制药公司，致力于通过利用开发不足的生物机会创造创新的癌症免疫疗法。具体而言，他们针对特征明确的生物学途径，并提供重要的科学数据支持其调节对癌症的免疫反应的重要性，并且无论是在开发中的分子还是在存在具有次优分布的分子。为了利用这些途径，他们建立了强大而高效的发现能力，以创建和优化高度分化的小分子免疫肿瘤产品候选物。自2015年成立以来，他们已经建立了广泛的小分子和抗体产品候选组合，他们计划共同开发内部组合产品。他们已经启动了两项最先进的候选产品的临床试验，这两种产品预计将在2018年产生数据，并且他们预计在2019年上半年将从他们的第一批产品组合中获得临床数据。他们计划推出两种附加产品候选人到2018年底进入临床试验阶段。Arcus团队的成员共同工作了10多年，在Tularik Inc.，Amgen，Inc.和Flexus Biosciences，Inc.等公司中发现创新的小分子产品候选人。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.062454},{"month":2,"riseRate":0.625,"avgChangeRate":0.1292},{"month":3,"riseRate":0.375,"avgChangeRate":-0.082593},{"month":4,"riseRate":0.375,"avgChangeRate":0.066961},{"month":5,"riseRate":0.5,"avgChangeRate":-0.026871},{"month":6,"riseRate":0.375,"avgChangeRate":-0.018808},{"month":7,"riseRate":0.5,"avgChangeRate":0.014802},{"month":8,"riseRate":0.625,"avgChangeRate":0.061887},{"month":9,"riseRate":0.5,"avgChangeRate":0.023516},{"month":10,"riseRate":0.375,"avgChangeRate":0.01429},{"month":11,"riseRate":0.875,"avgChangeRate":0.177539},{"month":12,"riseRate":0.25,"avgChangeRate":-0.02808}],"exchange":"NYSE","name":"Arcus Biosciences Inc.","nameEN":"Arcus Biosciences Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arcus Biosciences Inc.(RCUS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arcus Biosciences Inc.,RCUS,Arcus Biosciences Inc.股票,Arcus Biosciences Inc.股票老虎,Arcus Biosciences Inc.股票老虎国际,Arcus Biosciences Inc.行情,Arcus Biosciences Inc.股票行情,Arcus Biosciences Inc.股价,Arcus Biosciences Inc.股市,Arcus Biosciences Inc.股票价格,Arcus Biosciences Inc.股票交易,Arcus Biosciences Inc.股票购买,Arcus Biosciences Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arcus Biosciences Inc.(RCUS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arcus Biosciences Inc.(RCUS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}